Corporate Snapshot
ViRexx Medical Corp. is a biopharmaceutical company actively pursuing the development and commercialization of novel therapeutic products for the treatment of cancer, select solid tumors, and chronic viral infections, such as hepatitis B virus (HBV) and hepatitis C virus (HCV). The Company's technology is specifically directed toward harnessing the body's power to heal itself. In conjunction with these efforts, on December 10, 2004, ViRexx completed the acquisition of Edmonton-based AltaRex Medical Corp., which has developed antibody-based therapies to treat certain cancers by bolstering the immune system. With this acquisition, ViRexx now retains three key technology platforms from which to develop products, including: (1) the AIT® (Antibody-based ImmunoTherapy) technology platform, which takes an immunological approach to cancer treatment by attempting to stimulate an immune response through the use of monoclonal antibodies (MAbs) in a variety of cancer indications, including ovarian cancer (with OvaRex® MAb in Phase III clinical trials and the Company's most advanced stage product), breast cancer (with BrevaRex® MAb having completed a Phase I clinical trial), and prostate cancer (with ProstaRex® MAb in preclinical development); (2) the T-ACT™ (Targeted-Autothrombogenic Cancer Therapy) technology platform, which is designed to cut off the blood supply to tumors with the intent of causing the cancerous tissue to starve to death (with Occlusin™ 50 Injection currently in a Phase I trial in liver cancer patients and Occlusion™ 200 Injection in preclinical development for the treatment of uterine fibroids); and (3) the Chimigen™ Vaccine technology, a versatile technology platform that can be used as a therapeutic product to treat chronic viral infections and as a prophylactic vaccine in cases where the development of vaccines has been difficult. This platform is currently being used to create vaccines for the treatment of HBV and HCV infection, with HepaVaxx B and HepaVaxx C in preclinical stages, respectively.
* The Corporate Snapshot was last updated on October 4, 2005.
Latest Research
Quarterly
Update
2005-10-04
Click to View
Executive Informational Overview
2005-02-28
Click to View
Stock Information (PLB-TSX)